Nucleic acid nanotube liquid crystals

Patent metadata

Field	Value
Publication number	US-9371552-B2
Application number	US-201113090892-A
Country	US
Kind code	B2
Filing date	Apr 20, 2011
Priority date	Apr 21, 2006
Publication date	Jun 21, 2016
Grant date	Jun 21, 2016

Abstract

Compositions and methods for preparing nucleic acid nanotubes using DNA origami techniques are described, which provide for nanotubes of predictable and uniform length. The nucleic acid nanotubes thus formed are suitable as liquid crystal preparations enabling liquid-crystal NMR spectroscopy of proteins solubilized in detergent.

First claim

The invention claimed is:

1. A composition comprising nucleic acid nanotubes, each nanotube having a nanotube length, each nanotube formed from a single-stranded scaffold nucleic acid molecule and a plurality of staple oligonucleotides together forming a number of double-stranded nucleic acid helices joined by the single-stranded scaffold nucleic acid molecule, the nanotube length being the length of the single-stranded scaffold nucleic acid molecule divided by the number of double stranded nucleic acid helices comprising each nanotube, and wherein the length of the nucleic acid helices varies by no more than 20% of an average length of the helices, and wherein each of the nanotubes comprises at least three adjacent double-stranded helices.

2. The composition of claim 1 , wherein the nucleic acid nanotubes and the scaffold nucleic acid molecule are DNA.

3. The composition of claim 1 , wherein the distance between crossovers between any two adjacent helices is at least 10 base pairs.

4. The composition of claim 1 , wherein there are at least two crossovers between any pair of adjacent helices.

5. The composition of claim 1 , wherein each staple oligonucleotide comprises at least 7 nucleotides, and links at least two non-contiguous segments of the single-stranded scaffold nucleic acid molecule.

6. The composition of claim 5 , wherein each staple oligonucleotide comprises 32 nucleotides.

7. The composition of claim 5 , wherein each staple oligonucleotide comprises 54 nucleotides.

8. The composition of claim 1 , wherein each staple oligonucleotide comprises 42 nucleotides, and links three non-contiguous segments of the single-stranded scaffold nucleic acid molecule.

9. The composition of claim 1 , wherein the average length of the nucleic acid nanotubes is greater than 50 nanometers.

10. The composition of claim 1 , wherein the average length of the nucleic acid nanotubes is about 400 nanometers.

11. The composition of claim 1 , wherein each nucleic acid nanotube comprises at least four double-stranded nucleic acid helices.

12. The composition of claim 1 , wherein each nucleic acid nanotube comprises five double-stranded nucleic acid helices.

13. The composition of claim 1 , wherein each nucleic acid nanotube comprises six double-stranded nucleic acid helices.

14. The composition of claim 1 , wherein each nucleic acid nanotube comprises seven double-stranded nucleic acid helices.

15. The composition of claim 1 , wherein the length of the nucleic acid helices in the composition varies by no more than 10% of the average length of the helices in the composition.

16. The composition of claim 1 , wherein the nucleic acid nanotubes in the composition exist in a liquid crystalline phase.

17. The composition of claim 16 , wherein the nucleic acid nanotubes in the liquid crystalline phase are birefringent.

18. The composition of claim 1 , wherein the scaffold nucleic acid molecule is derived from a natural source.

19. The composition of claim 1 , wherein the scaffold nucleic acid molecule is derived from M13 DNA.

20. The composition of claim 1 , wherein the scaffold nucleic acid molecule is artificial.

21. The composition of claim 1 , further comprising a protein.

22. The composition of claim 21 , further comprising a detergent.

23. The composition of claim 22 , wherein the protein is a membrane protein.

24. The composition of claim 21 , wherein the protein is present at a concentration of at least 0.1 mM.

25. The composition of claim 1 , wherein the nucleic acid nanotubes comprise at least two monomers;
the first monomer having a first head end and a first tail end, said first head end comprising paired complementary strands of nucleic acids, and said first tail end comprising a plurality of first unpaired strands of nucleic acids; and
the second monomer having a second head end and a second tail end, said second head end comprising a plurality of second unpaired strands of nucleic acids, and said second tail end comprising paired complementary strands of nucleic acids; wherein
said first unpaired strands of nucleic acids are substantially complementary to said second unpaired strands of nucleic acids.

26. The composition of claim 1 , wherein the average length of the nucleic acid nanotubes is about 800 nanometers.

Assignees

• Shih William M
• Douglas Shawn M
• Chou James J
• Dana Farber Cancer Inst Inc
• Harvard College

Inventors

• Shih William M
• Douglas Shawn M
• Chou James J

Classifications

• C12P19/34 Primary

  Polynucleotides, e.g. nucleic acids, oligoribonucleotides · CPC title

• Y10T428/2975

  Tubular or cellular · CPC title

• Y10T436/24

  Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title